Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Gains from Investment Securities (2022 - 2025)

Coya Therapeutics' Gains from Investment Securities history spans 4 years, with the latest figure at $96502.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $96502.0; the TTM value through Sep 2025 reached $96502.0, changed N/A, while the annual FY2024 figure was $2.2 million, 96.51% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $96502.0 at Coya Therapeutics, roughly flat from $96502.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.2 million in Q2 2024 and bottomed at $16500.0 in Q1 2023.
  • The 4-year median for Gains from Investment Securities is $522492.0 (2022), against an average of $656093.6.
  • The largest annual shift saw Gains from Investment Securities soared 3332.81% in 2024 before it plummeted 95.62% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $478570.0 in 2022, then surged by 136.99% to $1.1 million in 2023, then skyrocketed by 94.21% to $2.2 million in 2024, then tumbled by 95.62% to $96502.0 in 2025.
  • Per Business Quant, the three most recent readings for COYA's Gains from Investment Securities are $96502.0 (Q3 2025), $96502.0 (Q2 2025), and $80060.0 (Q1 2025).